E3 Breast Cancer Taxotere Combination

PHASE2CompletedINTERVENTIONAL
Enrollment

64

Participants

Timeline

Start Date

January 31, 2006

Primary Completion Date

June 30, 2007

Study Completion Date

January 31, 2009

Conditions
Advanced Breast Cancer
Interventions
DRUG

Vandetanib (ZD6474)

once daily oral dose

DRUG

Docetaxel

intravenous infusion

Trial Locations (12)

Unknown

Research Site, Budapest

Research Site, Pécs

Research SIte, Bloemfontein

Research Site, Cape Town

Research Site, Observatory

Research Site, Barakaldo

Research SIte, Lleida

Research Site, Zaragoza

Research Site, Umeå

Research Site, Uppsala

Research Site, Västerås

Research Site, Taipei

All Listed Sponsors
lead

Genzyme, a Sanofi Company

INDUSTRY

NCT00494481 - E3 Breast Cancer Taxotere Combination | Biotech Hunter | Biotech Hunter